In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme gets rights to Alnylam's RNAi candidates for ATTR; rights expanded in new deal

Executive Summary

RNAi therapeutics developer Alnylam Pharmaceuticals Inc. has granted Sanofi’s Genzyme Corp. exclusive rights to develop and sell two of its candidates targeting transthyretin (TTR; a protein normally produced by the liver) to treat transthyretin-mediated amyloidosis (ATTR). Sanofi’s rights cover Japan and other Asia-Pacific countries, including Korea, Taiwan, China, India, Australia, and New Zealand.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies